ERBB2 and cancer: Resistance to trastuzumab emtansine may develop through the down-regulation or loss of HER2 expression, heterogeneous HER2 expression, receptor mutation, or expression of different HER2 isoform cancer cells may also develop resistance to the emtansine payload [40,41].